These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

Abbott Laboratories (NYSE: ABT ) reported upbeat second-quarter results and raised its full-year adjusted earnings outlook on Thursday. Adjusted earnings came in at $1.31 per share, topping the analyst consensus estimate of $1.28. Revenue increased 13% year over year to $12.59 billion, ahead of analysts’ expectations of $12.50 billion. On a comparable basis, sales rose 4.8%. "Our second-quarter results reflect the momentum we are building," Chairman and CEO Robert B. Ford said. "We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year." Abbott raised its full-year 2026 adjusted earnings guidance to a range of $5.45 to $5.60 per share from its prior forecast of $5.38 to $5.58. The updated range brackets the analyst consensus estimate of $5.49 p...